Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics today reported a 115 percent jump in its second quarter revenues, due to increased sales of the company's RosettaGX Reveal assay for the classification of indeterminate thyroid nodules (ITN).

The company also disclosed that the previously announced $2.9 million sale of its PersonalizeDx business has been delayed after the buyer, Pragmin Prognosis, failed to complete the transaction.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.